5-Amino-1MQ
Small-molecule NNMT inhibitor for adipose and metabolic research
5 mg vial · 50 mg vialpeptide · also known as BI 456906
A dual glucagon and GLP-1 receptor agonist from metabolic research.
Survodutide · 10 mg · Lyophilised vial
peptide · also known as BI 456906
A dual glucagon and GLP-1 receptor agonist from metabolic research.
In stock
Survodutide (BI 456906) is a synthetic peptide derived from glucagon that activates both the glucagon receptor and the GLP-1 receptor. It has been studied in clinical trials and is supplied here as a research reagent.
PubMed records selected for relevance to the compound. They describe published research, not outcomes or uses.
| Compound | Survodutide (BI 456906) |
|---|---|
| Type | Peptide |
| Selected presentation | 10 mg · Lyophilised vial |
| Form | Lyophilised powder in a sealed glass vial |
| Fill volume and concentration | Not applicable (lyophilised) |
| Label | CELVIVE wordmark, compound name, amount, "Purity: >99%", "For research use only" |
| Storage | -20 °C for long-term storage; 2 to 8 °C for under three months; away from light |
| Certificate of analysis | Not yet published online. Request for a batch |
| Research areas | Metabolic & GLP research |
| All presentations | 10 mg lyophilised vial · € 90.00 |